Perimenopause or Your Thyroid? Sorting Out Symptoms in Your 30s and 40s

Somewhere around 41, a lot of women start keeping a mental list. Sleep that breaks at 3am for no reason. A short fuse that does not match the situation. Words that go missing mid-sentence. Periods that are closer together, or heavier, or both. Bloating that showed up without a dietary change. A body that responds differently to the same food and the same workouts.

The list usually gets presented to a clinician one item at a time, and each item gets its own explanation. Stress. Not enough sleep. Perimenopause, probably. Labs are normal.

Each of those can be true and the list can still not add up. Because in this decade of life, perimenopause, thyroid dysfunction, iron deficiency, and gut problems produce an almost identical set of symptoms — and they frequently occur together, each one making the others harder to read.

Perimenopause starts earlier than most people are told

Perimenopause is the transition leading up to your final period, and it commonly begins in the early-to-mid 40s. For some women it starts in the late 30s. Menopause itself is a single point — twelve consecutive months without a period — and the average age in the US is around 51. The years before it are where most of the symptoms live.

The thing that causes the most confusion: your cycle can stay regular well into perimenopause. The hormonal shifts begin before the calendar changes. Progesterone tends to decline first, and estrogen does not simply fall — it fluctuates, sometimes to levels higher than in your 30s, then drops. That volatility, rather than low estrogen as such, drives a lot of what women notice first.

Which is why "my period is still like clockwork, so it can't be perimenopause" is not a safe conclusion. And why a single serum estradiol drawn on a random day often tells you very little. You are sampling one point on a curve that moves week to week.

Most health concerns have several contributors rather than one single cause. No specific diagnosis, outcome, or timeline of improvement is guaranteed.

The overlap problem

Here is why this is genuinely hard to sort out, and not a failure of anyone's attention.

Nearly every row has multiple checkmarks. So the question is almost never "is it hormones or thyroid?" — it is "which of these are contributing, and how much does each one matter for you?"

Thyroid

Thyroid disease is substantially more common in women, and the risk rises in exactly this age window — so perimenopause and new thyroid dysfunction often arrive together.

A TSH in range is a reasonable screen and is sufficient for many people. But TSH is a pituitary signal, not a direct measure of how much active hormone reaches your tissues. When symptoms persist and the story fits, free T4, free T3, reverse T3, and thyroid antibodies sometimes add something — antibodies in particular, because that is how Hashimoto's gets identified, often years before TSH drifts out of range. I have written in more detail about what a TSH alone can and cannot tell you, and there is a fuller picture of how I approach thyroid and Hashimoto's care.

Iron

Ferritin is one of the most under-read markers in women, and heavy or more frequent perimenopausal bleeding is a direct route to depleting it. Fatigue, hair shedding, breathlessness on stairs, and poor exercise tolerance can all come from ferritin that is technically "normal" but functionally low. It is on a standard panel and costs almost nothing to check — more on reading it properly here.

Gut

Bloating, reflux, and unpredictable bowels deserve attention on their own. They also matter because of what the gut does for everything else: absorbing the iron, B12, and magnesium that thyroid function and energy production depend on. Estrogen fluctuation genuinely does affect motility and the microbiome, so perimenopause can change digestion directly. If absorption is impaired, careful supplementing does not land. This is often the system I address first — not because it is always the origin, but because improvements there tend to make everything else respond better. More on gut health, IBS and SIBO.

Sleep and blood sugar

Declining progesterone affects sleep architecture, and broken sleep drives insulin resistance, which drives energy crashes and cravings, which affects what you eat, which affects your gut. This loop is one of the highest-yield places to intervene, and I wrote about the mechanism in sleep and blood sugar.

What testing is actually worth doing

My rule is the same across my practice: I order a test when the result is likely to change what I recommend. Not because it exists, not because it produces an impressive report.

For most women in this situation, a thorough history plus well-chosen foundational labs answers a surprising amount. That usually means a full thyroid panel including antibodies, ferritin with iron studies, CBC, a metabolic panel, B12, vitamin D, and a lipid panel — plus HbA1c and fasting insulin when metabolic symptoms are part of the picture. Much of this can go through insurance at a conventional laboratory.

Advanced testing earns its place in specific situations. A DUTCH test can show how you are metabolizing estrogen and what cortisol is doing across a full day — things a single serum draw cannot capture. A GI-MAP is worth considering when gut symptoms are persistent and the cause is unclear. But these are not starting points, and you should not need them to get a sensible plan.

What I would be cautious about: a panel of twenty hormones ordered before anyone has taken a careful history, or a protocol recommended on the basis of a test that was never going to change the recommendation.

Hormone therapy: what the FDA changed, and what it didn't

This is the most common question I get right now, so it is worth being precise.

In November 2025, the FDA announced it would remove the boxed warning from estrogen-containing menopausal hormone therapy products, following a review of the scientific literature. On February 12, 2026, it approved the first batch of label changes — six products, including Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva — removing boxed-warning language covering cardiovascular disease, breast cancer, and probable dementia. Around 29 manufacturers have submitted proposed labeling changes, and the rollout is still in progress.

That warning originated with the 2002 Women's Health Initiative results, which were widely reported in a way that did not reflect what the study actually found — particularly for women starting therapy near the onset of menopause rather than many years after. I went through that history in hormone therapy and heart risk.

What this change does: it brings the labeling closer to how the evidence has been read for some years, and it removes a warning that deterred a great many women, and clinicians, from a reasonable option.

What it does not do: make hormone therapy right for everyone. Individual risk still matters — a personal history of breast or other hormone-sensitive cancer, prior blood clot, stroke or heart attack, or active liver disease all change the calculation. Route and dose still matter. Timing still matters. A label change is not a recommendation, and it is not a substitute for a conversation about your particular history.

Hormone therapy is one of the tools I prescribe when it is appropriate — as a clinical decision inside a broader plan, not as a product. More on how I approach hormone health and menopause.

What actually helps, and in what order

Foundations first. Protein, strength training, blood sugar stability, sleep, and stress load are not the consolation prize when nothing interesting turns up on labs. In perimenopause they are the highest-yield interventions available, and they make everything layered on top work better. Muscle mass and bone density both become harder to defend in this decade, which is why resistance training moves from "good idea" to close to non-negotiable — and why creatine has a reasonable evidence base for women in perimenopause.

Correct what is measurably low. Iron, vitamin D, B12. Unglamorous and frequently the difference.

Treat the thyroid if it needs treating. If there is genuine hypothyroidism or Hashimoto's, no amount of hormone optimization elsewhere compensates.

Then consider hormone therapy, if it fits your history and your symptoms warrant it.

Targeted supplements, not stacks. I use supplements where there is a specific reason and something we are watching to judge whether it worked. If I cannot tell you why you are taking something, you should not be taking it. Patients have access to a vetted Fullscript dispensary at a standing discount, but the goal is always the shortest list that does the job.

Something to measure. Every plan should come with what to watch for and when to reassess. Otherwise you cannot tell the difference between something working and time passing.

Working with me in Colorado and Connecticut

I am licensed in both Colorado and Connecticut, and care is currently delivered by telehealth. You need to be physically in one of those two states at the time of each video visit — a licensing requirement rather than a preference — but you do not need to live near Denver or Hartford. Patients work with me from across both states, and there is more detail for Connecticut patients here.

There are a few ways to start, depending on how much support you want:

• Root Cause Review — $575. A two-visit evaluation: a 60-minute intake, my review of your existing records and labs, the pattern analysis between visits, and a 45-minute Review of Findings where you leave with personalized written recommendations. This is where most people begin, and the fee credits toward either program below if you enroll within 60 days.
• Reset — $2,995. Three months of implementation, for when the picture is reasonably clear and what it needs is consistent follow-through.
• Rebuild — $5,995. Six months, for when several systems are involved and the pattern is long-standing or layered.
• Integrative primary care if what you want is an ongoing provider rather than an evaluation — same thinking, carried forward as your regular care, with hormone therapy and thyroid management handled within it.

If you are not sure which fits — or whether any of this is the right step — a free 15-minute intro call is the quickest way to find out. I will tell you honestly if I think something else would serve you better.

Sources: FDA approves label changes for first batch of menopausal hormone therapy products · Harvard Health: FDA removes menopause hormone therapy black box warnings